Atea Pharmaceuticals Management
Management criteria checks 4/4
Atea Pharmaceuticals' CEO is Jean-Pierre Sommadossi, appointed in Jul 2012, has a tenure of 13.83 years. total yearly compensation is $3.40M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 8.29% of the company’s shares, worth $30.05M. The average tenure of the management team and the board of directors is 5.8 years and 5.8 years respectively.
Key information
Jean-Pierre Sommadossi
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 20.67% |
| CEO tenure | 13.8yrs |
| CEO ownership | 8.3% |
| Management average tenure | 5.8yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$3m | US$703k | -US$158m |
| Sep 30 2025 | n/a | n/a | -US$147m |
| Jun 30 2025 | n/a | n/a | -US$136m |
| Mar 31 2025 | n/a | n/a | -US$139m |
| Dec 31 2024 | US$4m | US$703k | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$174m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensation vs Market: Jean-Pierre's total compensation ($USD3.40M) is about average for companies of similar size in the US market ($USD2.64M).
Compensation vs Earnings: Jean-Pierre's compensation has been consistent with company performance over the past year.
CEO
Jean-Pierre Sommadossi (69 yo)
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 30.1m | |
| CFO, Executive VP of Legal & Secretary | 12.4yrs | US$1.69m | 1.03% $ 3.7m | |
| Chief Commercial Officer | 7.6yrs | US$1.22m | 0.21% $ 747.9k | |
| Chief Development Officer | 5.8yrs | US$1.77m | 0.16% $ 578.3k | |
| Chief Medical Officer | 5.8yrs | US$1.59m | 0.12% $ 435.3k | |
| Executive VP of Finance & Chief Accounting Officer | 4.3yrs | US$1.52m | 0.099% $ 359.4k | |
| Senior Vice President of Investor Relations & Corporate Communications | 5.3yrs | no data | no data | |
| Executive Vice President of Chemistry | no data | no data | no data | |
| Executive Vice President of Early Stage Development | no data | no data | no data | |
| Executive VP of Clinical Sciences & Project Management | 6.3yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs | 5.3yrs | no data | no data | |
| Executive Vice President of Preclinical Development | 4.3yrs | no data | no data |
Experienced Management: AVIR's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 30.1m | |
| Independent Director | 1.3yrs | US$415.33k | 0.057% $ 207.1k | |
| Independent Director | 5.6yrs | US$256.90k | 0.078% $ 284.3k | |
| Independent Director | 11.7yrs | US$249.40k | 0.14% $ 510.8k | |
| Lead Independent Director | 6.7yrs | US$282.90k | 0.63% $ 2.3m | |
| Independent Director | 11.5yrs | US$249.40k | 0.12% $ 431.3k | |
| Independent Director | 5.8yrs | US$251.90k | 0.11% $ 389.8k | |
| Independent Director | 5yrs | US$366.90k | 0.078% $ 284.3k | |
| Independent Director | less than a year | US$407.11k | no data |
Experienced Board: AVIR's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 06:00 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atea Pharmaceuticals, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |